全文获取类型
收费全文 | 755篇 |
免费 | 99篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 27篇 |
妇产科学 | 11篇 |
基础医学 | 85篇 |
口腔科学 | 27篇 |
临床医学 | 134篇 |
内科学 | 100篇 |
皮肤病学 | 17篇 |
神经病学 | 33篇 |
特种医学 | 173篇 |
外科学 | 60篇 |
综合类 | 14篇 |
现状与发展 | 1篇 |
预防医学 | 72篇 |
眼科学 | 2篇 |
药学 | 17篇 |
中国医学 | 1篇 |
肿瘤学 | 77篇 |
出版年
2023年 | 25篇 |
2022年 | 8篇 |
2021年 | 9篇 |
2020年 | 20篇 |
2019年 | 19篇 |
2018年 | 27篇 |
2017年 | 34篇 |
2016年 | 28篇 |
2015年 | 18篇 |
2014年 | 36篇 |
2013年 | 25篇 |
2012年 | 22篇 |
2011年 | 20篇 |
2010年 | 27篇 |
2009年 | 26篇 |
2008年 | 20篇 |
2007年 | 22篇 |
2006年 | 21篇 |
2005年 | 26篇 |
2004年 | 17篇 |
2003年 | 16篇 |
2002年 | 15篇 |
2001年 | 23篇 |
2000年 | 13篇 |
1999年 | 28篇 |
1998年 | 26篇 |
1997年 | 9篇 |
1996年 | 8篇 |
1995年 | 11篇 |
1994年 | 24篇 |
1993年 | 14篇 |
1992年 | 18篇 |
1991年 | 13篇 |
1990年 | 10篇 |
1989年 | 15篇 |
1988年 | 11篇 |
1987年 | 11篇 |
1986年 | 10篇 |
1985年 | 8篇 |
1984年 | 14篇 |
1983年 | 10篇 |
1981年 | 6篇 |
1980年 | 8篇 |
1979年 | 14篇 |
1978年 | 7篇 |
1977年 | 6篇 |
1975年 | 6篇 |
1974年 | 9篇 |
1970年 | 6篇 |
1969年 | 7篇 |
排序方式: 共有863条查询结果,搜索用时 15 毫秒
1.
2.
3.
Ross BD; Jacobson S; Villamil F; Korula J; Kreis R; Ernst T; Shonk T; Moats RA 《Radiology》1994,193(2):457
4.
5.
L. J. Haywood C. Faucett M. deGuzman K. Ell S. Norris E. Butts 《Journal of the National Medical Association》1998,90(4):241-252
The Rose Questionnaire, developed to facilitate screening for the presence of coronary artery disease, has shown good utility for white men and more variable utility among Latino, African-American, and female subjects. This study investigated its utility for prediction of outcome in patients with suspected myocardial infarction. A total of 1428 white, Latino, and African-American subjects completed questionnaires after emergency admission, which were correlated with diagnoses at the time of discharge from a public hospital and private hospital. Results indicated that subjects with positive questionnaires were less likely to have infarction confirmed at discharge, except for those with a prior history of myocardial infarction, than those with a negative response. These data are important in evaluating the overall utility of the Rose Questionnaire and the significance of angina. 相似文献
6.
7.
Caregivers in rural settings experience unmet needs. Some family caregivers in rural areas, either willingly or grudgingly, take on the role of caregiving as one of many responsibilities. A review of the literature reveals that the burden of the added responsibility results in physiological and psychological caregiver distress. The authors suggest some strategies to meet caregiver needs and outline areas where research is needed. 相似文献
8.
Butts K Pauly JM Daniel BL Kee S Norbash AM 《Journal of magnetic resonance imaging : JMRI》1999,9(4):586-595
Several methods were investigated to improve the depiction of biopsy needles in radiofrequency (RF)-refocused magnetic resonance imaging. Distortion correction is performed by the use of view angle tilting (VAT): a gradient is employed on the slice-select axis during readout. Needle conspicuity is increased by offsetting the gradient echo from the spin echo and by inverting the 90 degrees RF pulse slice-select gradient. VAT effectively re-registers in-plane shifts. Since this method changes the projection angle through the slice, some structures appear blurred, while other structures appear sharper. VAT does not correct errors in slice selection. Offsetting the spin echo from the gradient echo increases needle conspicuity but can result in a shift in the apparent location of the needle. Inverting the 90 degrees slice-select gradient effectively increases the needle conspicuity with no shift in the needle location. These methods provide an easy and interactive means to manipulate needle artifacts but should be used cautiously. 相似文献
9.
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. 总被引:6,自引:0,他引:6
U Gatzemeier G Groth C Butts N Van Zandwijk F Shepherd A Ardizzoni C Barton P Ghahramani V Hirsh 《Annals of oncology》2004,15(1):19-27
BACKGROUND: Trastuzumab provides significant clinical benefits in HER2-positive metastatic breast cancer patients when administered in combination with chemotherapy. Chemotherapy has also been shown to be beneficial in some patients with advanced non-small-cell lung cancer (NSCLC). The present randomized phase II trial examined the effect of adding trastuzumab to a standard chemotherapeutic combination (gemcitabine-cisplatin) in patients with HER2-positive NSCLC. PATIENTS AND METHODS: Patients with untreated stage IIIB/IV HER2-positive NSCLC received up to six 21-day cycles of gemcitabine 1250 mg/m(2) (days 1 and 8) and cisplatin 75 mg/m(2) (day 1). Patients in the trastuzumab arm received trastuzumab 4 mg/kg intravenously (i.v.) followed by 2 mg/kg/week i.v. until progression. RESULTS: Of 619 patients screened, 103 were eligible. Fifty-one patients were treated with trastuzumab plus gemcitabine-cisplatin and 50 with gemcitabine-cisplatin alone. Efficacy was similar in the trastuzumab and control arms: response rate 36% versus 41%; median time to progression 6.3 versus 7.2 months; and median progression-free survival (PFS) 6.1 versus 7 months. Response rate (83%) and median PFS (8.5 months) appeared relatively good in the six trastuzumab-treated patients with HER2 3+ or fluorescence in situ hybridization (FISH)-positive NSCLC. Addition of trastuzumab to gemcitabine-cisplatin was well tolerated, side-effects were as expected, and trastuzumab did not exacerbate the known toxicity of gemcitabine and cisplatin. Symptomatic cardiotoxicity was observed in one trastuzumab-treated patient. Serum trastuzumab concentrations in the presence of gemcitabine-cisplatin were comparable to those of trastuzumab alone. CONCLUSIONS: Trastuzumab plus gemcitabine-cisplatin is well tolerated. Clinical benefit was not observed. Although HER2 3+/FISH-positive patients may benefit from trastuzumab, the subgroup is too small to provide definitive information. No significant effect of gemcitabine-cisplatin on trastuzumab pharmacokinetics was observed. 相似文献
10.
Charles Butts Nevin Murray Andrew Maksymiuk Glenwood Goss Ernie Marshall Denis Soulières Yvon Cormier Peter Ellis Allan Price Ravinder Sawhney Mary Davis Janine Mansi Colum Smith Dimitrios Vergidis Paul Ellis Mary MacNeil Martin Palmer 《Journal of clinical oncology》2005,23(27):6674-6681
PURPOSE: To evaluate the effect of BLP25 liposome vaccine (L-BLP25) on survival and toxicity in patients with stage IIIB and IV non-small-cell lung cancer (NSCLC). Secondary objectives included health-related quality of life (QOL) and immune responses elicited by L-BLP25. PATIENTS AND METHODS: Patients with an Eastern Cooperative Oncology Group performance status of 0 to 2 and stable or responding stage IIIB or IV NSCLC after any first-line chemotherapy were prestratified by stage and randomly assigned to either L-BLP25 plus best supportive care (BSC) or BSC alone. Patients in the L-BLP25 arm received a single intravenous dose of cyclophosphamide 300 mg/m2 followed by eight weekly subcutaneous immunizations with L-BLP25 (1,000 microg). Subsequent immunizations were administered at 6-week intervals. RESULTS: The survival results indicate a median survival time of 4.4 months longer for patients randomly assigned to the L-BLP25 arm (88 patients) compared with patients assigned to the BSC arm (83 patients; adjusted hazard ratio [HR] = 0.739; 95% CI, 0.509 to 1.073; P = .112). The greatest effect was observed in stage IIIB locoregional (LR) patients, for whom the median survival time for the L-BLP25 arm has not yet been reached compared with 13.3 months for the BSC arm (adjusted HR = 0.524; 95% CI, 0.261 to 1.052; P = .069). No significant toxicity was observed. QOL was maintained longer in patients on the L-BLP25 arm. CONCLUSION: L-BLP25 maintenance therapy in patients with advanced NSCLC is feasible with minimal toxicity. The survival difference of 4.4 months observed with the vaccine did not reach statistical significance. In the subgroup of patients with stage IIIB LR disease, a strong trend in 2-year survival in favor of L-BLP25 was observed. 相似文献